Det forventes derfor ikke, at Zonegran påvirker farmakokinetikken af andre lægemidler via cytochrom P450- mediere mekanismer, som det er vist for carbamazepin, phenytoin, ethinylestradiol og desipramin in vivo.
Therefore Zonegran is not expected to affect the pharmacokinetics of other medicinal products via cytochrome P450-mediated mechanisms, as demonstrated for carbamazepine, phenytoin, ethinylestradiol and desipramine in vivo.